Figure 5 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Figure 5 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

<p>Activating <i>TMPRSS2-ERG</i> fusions and the downstream cistrome are marked by 5hmC. <b>A</b> and <b>B,</b> 5hmC locations and hypomethylation at the <i>ERG</i> and <i>TMPRSS2</i> loci. 5hmC levels are shown as frequency of sample...

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Martin Sjöström (14845882) (author)
Drugi avtorji:	Shuang G. Zhao (12227671) (author), Samuel Levy (14960811) (author), Meng Zhang (14960814) (author), Yuhong Ning (279537) (author), Raunak Shrestha (14949693) (author), Arian Lundberg (14960817) (author), Cameron Herberts (14960820) (author), Adam Foye (14960823) (author), Rahul Aggarwal (14960826) (author), Junjie T. Hua (14960829) (author), Haolong Li (1532230) (author), Anna Bergamaschi (14960832) (author), Corinne Maurice-Dror (14960835) (author), Ashutosh Maheshwari (14960838) (author), Sujun Chen (3553841) (author), Sarah W.S. Ng (14960841) (author), Wenbin Ye (14960844) (author), Jessica Petricca (14960847) (author), Michael Fraser (522709) (author), Lisa Chesner (14960850) (author), Marc D. Perry (14960853) (author), Thaidy Moreno-Rodriguez (14960856) (author), William S. Chen (14960859) (author), Joshi J. Alumkal (14950518) (author), Jonathan Chou (14957015) (author), Alicia K. Morgans (5600567) (author), Tomasz M. Beer (14960862) (author), George V. Thomas (13187926) (author), Martin Gleave (146446) (author), Paul Lloyd (14960865) (author), Tierney Phillips (4664332) (author), Erin McCarthy (14960868) (author), Michael C. Haffner (14960871) (author), Amina Zoubeidi (14960874) (author), Matti Annala (219688) (author), Robert E. Reiter (14960877) (author), Matthew B. Rettig (14960880) (author), Owen N. Witte (14960883) (author), Lawrence Fong (14960886) (author), Rohit Bose (14960889) (author), Franklin W. Huang (10726678) (author), Jianhua Luo (14960892) (author), Anders Bjartell (199682) (author), Joshua M. Lang (12227674) (author), Nupam P. Mahajan (14960895) (author), Primo N. Lara (13009812) (author), Christopher P. Evans (14960898) (author), Phuoc T. Tran (14960901) (author), Edwin M. Posadas (14960904) (author), Chuan He (178952) (author), Xiao-Long Cui (2020402) (author), Jiaoti Huang (88989) (author), Wilbert Zwart (14960907) (author), Luke A. Gilbert (5513207) (author), Christopher A. Maher (14960910) (author), Paul C. Boutros (14954698) (author), Kim N. Chi (14960913) (author), Alan Ashworth (14957030) (author), Eric J. Small (14960916) (author), Housheng H. He (14960919) (author), Alexander W. Wyatt (14960922) (author), David A. Quigley (14957012) (author), Felix Y. Feng (14845891) (author)
Izdano:	2025
Teme:	Cancer Cancer Risk Factors Molecular and Cellular Biology Methods and Technology Epigenetics Epigenomics Genitourinary Cancers Prostate cancer Liquid Biopsy
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Figure 1 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
od: Martin Sjöström (14845882)
Izdano: (2025)

Figure 2 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
od: Martin Sjöström (14845882)
Izdano: (2025)

Figure 3 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
od: Martin Sjöström (14845882)
Izdano: (2025)

Figure 4 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
od: Martin Sjöström (14845882)
Izdano: (2025)

Figure 6 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
od: Martin Sjöström (14845882)
Izdano: (2025)

Figure 7 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
od: Martin Sjöström (14845882)
Izdano: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
od: Martin Sjöström (14845882)
Izdano: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
od: Martin Sjöström (14845882)
Izdano: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
od: Martin Sjöström (14845882)
Izdano: (2025)

Supplementary Figure 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
od: Alex Chehrazi-Raffle (17079582)
Izdano: (2025)

Supplementary Data 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
od: Alex Chehrazi-Raffle (17079582)
Izdano: (2025)

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
od: Sofie H. Tolmeijer (15313251)
Izdano: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
od: Sofie H. Tolmeijer (15313251)
Izdano: (2025)

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
od: Sofie H. Tolmeijer (15313251)
Izdano: (2025)

Supplementary Data from DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations
od: John Gallon (15096459)
Izdano: (2025)

Supplementary Data 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
od: Arian Lundberg (14960817)
Izdano: (2025)

Supplementary Data 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
od: Arian Lundberg (14960817)
Izdano: (2025)

Supplementary Table 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
od: Arian Lundberg (14960817)
Izdano: (2025)

Supplementary Table 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
od: Arian Lundberg (14960817)
Izdano: (2025)

Supplementary Table 3. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
od: Arian Lundberg (14960817)
Izdano: (2025)

Supplementary Data 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
od: Hong Qiu (14963144)
Izdano: (2025)

Supplementary Data 2 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
od: Hong Qiu (14963144)
Izdano: (2025)

Supplementary Table S5 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
od: Abdullah A. Osman (15056323)
Izdano: (2025)

Supplementary Table S1 from G-Quadruplex Structures Are Key Modulators of Somatic Structural Variants in Cancers
od: Rongxin Zhang (15293341)
Izdano: (2025)

Supplementary Table S2 from G-Quadruplex Structures Are Key Modulators of Somatic Structural Variants in Cancers
od: Rongxin Zhang (15293341)
Izdano: (2025)

Supplementary Figure S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
od: Abdullah A. Osman (15056323)
Izdano: (2025)

Supplementary Table S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
od: Abdullah A. Osman (15056323)
Izdano: (2025)

Supplementary Table S2 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
od: Abdullah A. Osman (15056323)
Izdano: (2025)

Supplementary Table S3 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
od: Abdullah A. Osman (15056323)
Izdano: (2025)

Supplementary Table S4 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
od: Abdullah A. Osman (15056323)
Izdano: (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
od: James R. Larkin (14936324)
Izdano: (2025)

Supplementary Tables 1 from Proteostasis Modulation in Germline Missense von Hippel Lindau Disease
od: Prashant Chittiboina (15367044)
Izdano: (2025)

Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
od: Stephanie Lheureux (16797697)
Izdano: (2025)

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
od: Emil Christensen (15054394)
Izdano: (2025)

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
od: Emil Christensen (15054394)
Izdano: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
od: Kala Visvanathan (14952973)
Izdano: (2025)

Figure S5 from Oncogenic Transformation Drives DNA Methylation Loss and Transcriptional Activation at Transposable Element Loci
od: Tomas Kanholm (14952351)
Izdano: (2025)

Supplementary Data from β-Catenin–Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer
od: Dipika R. Mohan (15011204)
Izdano: (2025)

Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
od: Stephanie Lheureux (16797697)
Izdano: (2025)

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
od: Stephanie Lheureux (16797697)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_he8fdprohtm0e49l2jqr4g1s1b